Yesim Eralp

Articles by Yesim Eralp

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

ByNagi El Saghir,Yoon Sim Yap,Yesim Eralp,Seock-Ah Im,Hamdy Abdel Azim,Julie Rihani,Nikita Volkov,Shin-Cheh Chen,Hakan Harputluoglu,Patrapim Sunpaweravong,Yuan-Ching Chang,Teresa Delgar Alfaro,Jiwen Wu,Huilin Hu,Melissa Gao,Yen-Shen Lu

August 15th 2024

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

ByMelissa Gao,Yen-Shen Lu,Eznal Izwadi Bin Mohd Mahidin,Hamdy Abdel Azim,Yesim Eralp,Yoon Sim Yap,Seock-Ah Im,Julie Rihani,James Bowles,Teresa Delgar Alfaro,Jiwen Wu,Khemaies Slimane,Nagi El Saghir

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Acting on a HER2 Result and Navigating Access to Therapy

Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC

FDA Clears TriNav Advance for Expanded Liver Embolization Access

Patient-Centered Treatment Transitions in HR+/HER2− mBC